Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues
Autor: | José Ángel Díaz Pérez, Ana Ortolá Buigues, Manuela Jorquera Moya, Irene Crespo Hernandez |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Octreotide Case Report Lanreotide lcsh:RC254-282 Meningioma 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Somatostatin receptors medicine.diagnostic_test Somatostatin receptor business.industry Magnetic resonance imaging medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Radiation therapy Somatostatin chemistry 030220 oncology & carcinogenesis Radiological weapon Meningeal neoplasms Radiology business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 9, Iss 2, Pp 520-525 (2016) Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
ISSN: | 1662-6575 |
Popis: | Medical treatment of meningiomas is reserved for cases in which surgery and radiotherapy have failed. Given that a high percentage of meningiomas express somatostatin receptors, treatment with somatostatin analogues has been proposed. In addition, these medications have been shown to have an antiproliferative and antiangiogenic effect in vitro. To date, very few cases with clinical response and none with radiological response have been described. The case described here is the first to report a radiological response. A 76-year-old Caucasian male was first diagnosed with unresectable meningioma at age 47. The patient experienced multiple recurrences and underwent three surgeries and radiotherapy over the years from the initial diagnosis. Despite treatment, the disease continued its progression. Based on an Octreoscan positive for tumour uptake, therapy with extended-release somatostatin analogues was started. Although no clinical neurological improvement was observed, magnetic resonance imaging scans revealed a discreet but continuous radiological response over time. After >2 years of continuous administration of lanreotide, the patient remains progression free. In highly selected cases, somatostatin analogue treatment for meningioma may be beneficial. Based on our findings, treatment with somatostatin analogues should be maintained longer than previously described before evaluating treatment response. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |